Matthijs Meijers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthijs Meijers has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Michael Lässig
Affiliation Institute for Biological Physics, University of Cologne, Cologne, Germany
5 shared publications - Denis Ruchnewitz
Institute for Biological Physics, University of Cologne
4 shared publications - Henning Gruell
Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany
3 shared publications - Christoph Kreer
Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
2 shared publications - Florian Klein
Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne
2 shared publications Jan Eberhardt
Institute for Biological Physics, University of Cologne
2 shared publications
Latest Publications
- Open Access
Detection of pre-existing humoral immunity against influenza virus H5N1 clade 2.3.4.4b in unexposed individuals
The repeated spill-over of Influenza A virus H5N1 clade 2.3.4.4b from cattle to humans highlights the risk of a human H5N1 pandemic. Given the impact of pre-existing immunity on the course and severity of viral infections, we assessed in detail the humoral immunity against the H5N1 A/Texas/37/2024 isolate in H5N1-naïve individuals. To this end, we performed complementary binding and neutralization assays on 66 subjects and ranked activities among a panel of 76 influenza A virus isolates. We detected low but distinct cross-neutralizing titers against A/Texas/37/2024 with a 3.9 to 15.6-fold reduction compared to selected H1N1 or H3N2 strains. Moreover, by cloning and evaluating 136 monoclonal antibodies from single memory B cells, we identified potent A/Texas/37/2024-neutralizing monoclonal antibodies in five out of six investigated individuals. These antibodies predominantly utilize VH1-69 gene segments, cross-neutralize H1, and compete with antibodies targeting the HA stem. Our findings demonstrate partial pre-existing humoral immunity to A/Texas/37/2024 in H5N1-naïve individuals.
Open AccessDetection of pre-existing humoral immunity against influenza virus H5N1 clade 2.3.4.4b in unexposed individuals
The repeated spill-over of Influenza A virus H5N1 clade 2.3.4.4b from cattle to humans highlights the risk of a human H5N1 pandemic. Given the impact of pre-existing immunity on the course and severity of viral infections, we assessed in detail the humoral immunity against the H5N1 A/Texas/37/2024 isolate in H5N1-naïve individuals. To this end, we performed complementary binding and neutralization assays on 66 subjects and ranked activities among a panel of 76 influenza A virus isolates. We detected low but distinct cross-neutralizing titers against A/Texas/37/2024 with a 3.9 to 15.6-fold reduction compared to selected H1N1 or H3N2 strains. Moreover, by cloning and evaluating 136 monoclonal antibodies from single memory B cells, we identified potent A/Texas/37/2024-neutralizing monoclonal antibodies in five out of six investigated individuals. These antibodies predominantly utilize VH1-69 gene segments, cross-neutralize H1, and compete with antibodies targeting the HA stem. Our findings demonstrate partial pre-existing humoral immunity to A/Texas/37/2024 in H5N1-naïve individuals.
- Open Access
Concepts and methods for predicting viral evolution
Summary: The seasonal human influenza virus undergoes rapid evolution, leading to significant changes in circulating viral strains from year to year. These changes are typically driven by adaptive mutations, particularly in the antigenic epitopes, the regions of the viral surface protein haemagglutinin targeted by human antibodies. Here we describe a consistent set of methods for data-driven predictive analysis of viral evolution. Our pipeline integrates four types of data: (1) sequence data of viral isolates collected on a worldwide scale, (2) epidemiological data on incidences, (3) antigenic characterization of circulating viruses, and (4) intrinsic viral phenotypes. From the combined analysis of these data, we obtain estimates of relative fitness for circulating strains and predictions of clade frequencies for periods of up to one year. Furthermore, we obtain comparative estimates of protection against future viral populations for candidate vaccine strains, providing a basis for pre-emptive vaccine strain selection. Continuously updated predictions obtained from the prediction pipeline for influenza and SARS-CoV-2 are available on the website previr.app .
Open AccessConcepts and methods for predicting viral evolution
Summary: The seasonal human influenza virus undergoes rapid evolution, leading to significant changes in circulating viral strains from year to year. These changes are typically driven by adaptive mutations, particularly in the antigenic epitopes, the regions of the viral surface protein haemagglutinin targeted by human antibodies. Here we describe a consistent set of methods for data-driven predictive analysis of viral evolution. Our pipeline integrates four types of data: (1) sequence data of viral isolates collected on a worldwide scale, (2) epidemiological data on incidences, (3) antigenic characterization of circulating viruses, and (4) intrinsic viral phenotypes. From the combined analysis of these data, we obtain estimates of relative fitness for circulating strains and predictions of clade frequencies for periods of up to one year. Furthermore, we obtain comparative estimates of protection against future viral populations for candidate vaccine strains, providing a basis for pre-emptive vaccine strain selection. Continuously updated predictions obtained from the prediction pipeline for influenza and SARS-CoV-2 are available on the website previr.app .
- Top Cited PapersOpen Access
Population immunity predicts evolutionary trajectories of SARS-CoV-2
- Open Access
Vaccination shapes evolutionary trajectories of SARS-CoV-2
The large-scale evolution of the SARS-CoV-2 virus has been marked by rapid turnover of genetic clades. New variants show intrinsic changes, notably increased transmissibility, as well as anti-genic changes that reduce the cross-immunity induced by previous infections or vaccinations 1–4 . How this functional variation shapes the global evolutionary dynamics has remained unclear. Here we show that selection induced by vaccination impacts on the recent antigenic evolution of SARS-CoV-2; other relevant forces include intrinsic selection and antigenic selection induced by previous infections. We obtain these results from a fitness model with intrinsic and antigenic fitness components. To infer model parameters, we combine time-resolved sequence data 5 , epidemiological records 6,7 , and cross-neutralisation assays 8–10 . This model accurately captures the large-scale evolutionary dynamics of SARS-CoV-2 in multiple geographical regions. In particular, it quantifies how recent vaccinations and infections affect the speed of frequency shifts between viral variants. Our results show that timely neutralisation data can be harvested to identify hotspots of antigenic selection and to predict the impact of vaccination on viral evolution.
Open AccessVaccination shapes evolutionary trajectories of SARS-CoV-2
The large-scale evolution of the SARS-CoV-2 virus has been marked by rapid turnover of genetic clades. New variants show intrinsic changes, notably increased transmissibility, as well as anti-genic changes that reduce the cross-immunity induced by previous infections or vaccinations 1–4 . How this functional variation shapes the global evolutionary dynamics has remained unclear. Here we show that selection induced by vaccination impacts on the recent antigenic evolution of SARS-CoV-2; other relevant forces include intrinsic selection and antigenic selection induced by previous infections. We obtain these results from a fitness model with intrinsic and antigenic fitness components. To infer model parameters, we combine time-resolved sequence data 5 , epidemiological records 6,7 , and cross-neutralisation assays 8–10 . This model accurately captures the large-scale evolutionary dynamics of SARS-CoV-2 in multiple geographical regions. In particular, it quantifies how recent vaccinations and infections affect the speed of frequency shifts between viral variants. Our results show that timely neutralisation data can be harvested to identify hotspots of antigenic selection and to predict the impact of vaccination on viral evolution.
- 18 December 2021
- Published by Elsevier in Cell Host & Microbe
- Vol. 30 (1) , 69-82.e10
Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
- 18 December 2021
- Published by Elsevier in Cell Host & Microbe
- Vol. 30 (1) , 69-82.e10
Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
- Open Access
- 23 July 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (30)
Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody
Significance: Broadly neutralizing antibodies (bnAbs) show promise for antibody-mediated prevention or treatment of HIV-1 infection. Recent clinical trials, however, indicate that the virus can evolve resistance mutations that escape neutralization by bnAbs. Here, we establish a fitness model for the escape dynamics of HIV in humans. We show that this model can be applied universally across different human hosts, providing a proof of principle that the in vivo response of HIV to bnAb therapies is predictable. Our analysis identifies a fitness trade-off in viral evolution that can inform antibody design and therapy protocols.
- 23 July 2021
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (30)
Open AccessPredicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody
Significance: Broadly neutralizing antibodies (bnAbs) show promise for antibody-mediated prevention or treatment of HIV-1 infection. Recent clinical trials, however, indicate that the virus can evolve resistance mutations that escape neutralization by bnAbs. Here, we establish a fitness model for the escape dynamics of HIV in humans. We show that this model can be applied universally across different human hosts, providing a proof of principle that the in vivo response of HIV to bnAb therapies is predictable. Our analysis identifies a fitness trade-off in viral evolution that can inform antibody design and therapy protocols.